Search | Clinical Trials Finder

Conditions: Advanced Breast Cancer, Treatment-Refractory Solid Tumors, Retinoblastoma Deficiency, SCLC, Soft Tissue Sarcoma, Endometrial Cancer, Bladder Cancer
Interventions: Palbociclib Oral Product, TAS-116; Drug
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Pelvic Floor Disorders, Sexual Dysfunction, Stress Incontinence
Interventions: vSculpt; Device
Lead sponsor: Joylux, Inc.; Other
Eligibility: 30 Years to 59 Years · Female only
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Bellevue, Washington • Seattle, Washington

Conditions: Vesicoureteral Reflux
Interventions: Parental information, Play therapy; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 2 Years to 10 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Interventions: Ruvidar® (TLD-1433) bladder infusion and PDT; Combination Product
Lead sponsor: Theralase® Technologies Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 10
States / cities: Chicago, Illinois • Greenwood, Indiana • Syracuse, New York + 7 more

Conditions: Bladder Cancer
Interventions: personalized ultrafractionated stereotactic ablative radiotherapy; Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Overactive Bladder
Interventions: ZIDA Control Sock; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Non-muscle-invasive Bladder Cancer
Interventions: Not listed
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Dallas, Texas • San Antonio, Texas

Conditions: Breast Cancer, Hodgkin Lymphoma, Kidney Cancer, Leukemia, Lymphoid Leukemia, Multiple Myeloma, Myeloid Leukemia, Monocytic Leukemia, Prostate Cancer, Bladder Cancer
Interventions: Assessment tool IA3-CP with SDoH, Assessment tool IA3-CP without SDoH; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 65 Years to 111 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Spinal Cord Injury, Neurogenic Bladder (NB), Neurogenic Lower Urinary Tract Dysfunction, Multiple Sclerosis, Spina Bifida, Urinary Tract Infection(UTI)
Interventions: Gentamicin, Lactobacillus Rhamnosus GG; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Pittsburgh, Pennsylvania

Conditions: Overactive Bladder, Fecal Incontinence, Urinary Retention
Interventions: Sacral Neuromodulation; Device
Lead sponsor: MedtronicNeuro; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 7
States / cities: Indianapolis, Indiana • New Orleans, Louisiana • Rochester, Minnesota + 3 more

Conditions: Bladder Pain Syndrome, Interstitial Cystitis
Interventions: Acupuncture, Behavioral management, Physical therapy; Other · Behavioral
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Bladder Cancer
Interventions: cisplatin, 5-fluorouracil, Mitomycin, Three-Dimensional Conformal Radiation Therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2023
U.S. locations: 13
States / cities: Atlanta, Georgia • Baltimore, Maryland • Fall River, Massachusetts + 9 more

Conditions: Bladder Cancer
Interventions: Prostate capsule-sparing radical cystectomy, Nerve sparing radical cystectomy; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: Interstitial Cystitis, Bladder Pain Syndrome, Microbial Colonization
Interventions: Heparin & Alkalinized Lidocaine Bladder Instillation; Drug
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Bladder Cancer
Interventions: hexaminolevulinate, biopsy, cystoscopy; Drug · Procedure
Lead sponsor: Photocure; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pelvic Organ Prolapse, Urogenital Prolapse, Vaginal Vault Prolapse, Cystocele, Uterine Prolapse, Vaginal Prolapse, Pelvic Floor Disorders
Interventions: Conjugated Estrogens Cream, Placebo Cream; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 48 Years and older · Female only
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 3
States / cities: Birmingham, Alabama • Providence, Rhode Island • Dallas, Texas

Conditions: Urinary Bladder Overactive, Urinary Bladder Diseases\Urologic Diseases, Overactive Bladder, Urgency Incontinence
Interventions: Solifenacin succinate, Mirabegron, Placebo to match solifenacin succinate, Placebo to match mirabegron; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 3,527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 121
States / cities: Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 96 more

Conditions: Bladder Cancer, Kidney Cancer, Lung Cancer
Interventions: tucotuzumab celmoleukin; Biological
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • New York, New York

Conditions: Urinary Bladder Neoplasms
Interventions: TAR-200, Cetrelimab; Drug · Biological
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 41
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 32 more

Conditions: Advanced Solid Tumors, HER2 Mutation
Interventions: BAY2927088; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 11
States / cities: Birmingham, Alabama • Duarte, California • Fort Myers, Florida + 8 more

Conditions: Interstitial Cystitis, Bladder Pain Syndrome
Interventions: Cannabidiol vaginal suppository, Placebo vaginal suppository; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Urinary Tract Infections
Interventions: Gentamicin, Placebo; Drug
Lead sponsor: Gillette Children's Specialty Healthcare; Other
Eligibility: 16 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Overactive Bladder, Urinary Urgency, Urinary Bladder, Overactive, Urinary Incontinence, Urge, Caffeine, Alcohol Drinking, Lower Urinary Tract Symptoms
Interventions: Reducing Potentially Irritating Beverages, Adopting the USDA Healthy Eating Habits; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Urothelial Cancer, Melanoma
Interventions: PF-07329640, sasanlimab, bevacizumab; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 4
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 1 more

Search by objective public record fields.

TAS-116 Plus Palbociclib in Breast and Rb-null Cancer

A Long-term Evaluation of a Novel Intravaginal Device

Parent Education and Medical Play: A Comparison of Psychological Preparation Strategies for Voiding Cystourethrogram

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer

Add-On ZIDA Sock Therapy for Overactive Bladder

Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)

Integrated Actionable Aging Assessment for Cancer Patients Pilot

Coupled Gentamicin-Lactobacillus Rhamnosus in NLUTD

Pelvic Health Electrically Evoked Recording (PEER) 2 Study

Acupuncture First for IC/BPS

Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer

Evaluating Safety and Efficacy of Prostate-sparing Radical Cystectomy

The Female Microbiome in Patients Undergoing Bladder Instillation Therapy

Cystoscopy and Hexyl 5-Aminolevulinate in Detecting Carcinoma In Situ in Patients With Bladder Cancer

Investigation to Minimize Prolapse Recurrence of the Vagina Using Estrogen

This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder

Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment

A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

The CBD-IC Randomized Controlled Trial: Evaluation of Hemp Cannabidiol SuppositoRies for Pain and Urinary SymptOms in INterstitial Cystitis (CHRONIC)

Gentamicin Bladder Instillation Trial

Fluids Affecting Bladder Urgency and Lower Urinary Symptoms

A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination